Richard F. Riedel, MD
Department / Division
Medicine /
Medicine - Oncology
Address
DUMC 3198
Durham, NC 27710
Appointment Telephone
1-877-727-2385
Office Telephone
919-681-6932
Fax Telephone
919-684-5163
- MD, Jefferson Medical College of Thomas Jefferson University (Pennsylvania), 2000
- Internal Medicine, Duke University Medical Center, 2000-2003
- Internal Medicine, Chief Resident, Durham VA Medical Center, 2004-2005
- Hematology/Medical Oncology, Duke University Medical Center, 2003-2004, 2005-2007
Clinical Interests
Treatment and management of patients with soft-tissue and bone sarcomas
Research Interests
Novel therapies for soft tissue and bone sarcomas
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Ariad Pharmaceuticals, Inc.
- Bio-Tech Prosthetics and Orthotics
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Novartis
- Pfizer Inc.
Representative Publications
Palta M, Riedel RF, Vredenburgh JJ, Cummings TJ, Green S, Chang Z, Kirkpatrick JP. Primary meningeal rhabdomyosarcoma. Sarcoma. 2011;2011:312802.
(2011)
Abstract
Riedel RF. Systemic therapy for advanced soft tissue sarcomas: Highlighting novel therapies and treatment approaches. Cancer. 2011 Aug 11.
(2011)
Abstract
Smith JL, Riedel RF. Emerging therapeutic targets for soft tissue sarcoma. Curr Oncol Rep. 2011 Aug;13(4):350-8.
(2011)
Abstract
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM 3rd, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J, . Soft tissue sarcoma. J Natl Compr Canc Netw. 2010 Jun;8(6):630-74.
(2010)
Abstract
Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4.
(2010)
Abstract
Mito JK, Riedel RF, Dodd L, Lahat G, Lazar AJ, Dodd RD, Stangenberg L, Eward WC, Hornicek FJ, Yoon SS, Brigman BE, Jacks T, Lev D, Mukherjee S, Kirsch DG. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One. 2009;4(11):e8075.
(2009)
Abstract
Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE. The clinical management of chondrosarcoma. Curr Treat Options Oncol. 2009 Apr;10(1-2):94-106.
(2009)
Abstract
Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther. 2008 Oct;7(10):3141-9.
(2008)
Abstract
Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol. 2007 Oct 1;25(28):4350-7.
(2007)
Abstract
Riedel RF, Andrews C, Garst J, Dunphy F, Herndon JE 2nd, Blackwell S, Barbour S, Crawford J. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. J Thorac Oncol. 2007 Jun;2(6):520-5.
(2007)
Abstract
Riedel RF, Burfeind WR Jr. Thymoma: benign appearance, malignant potential. Oncologist. 2006 Sep;11(8):887-94.
(2006)
Abstract
Riedel RF, Crawford J, Dunphy F, Herndon JE 2nd, Garst J, Kelley MJ. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer. 2006 Dec;54(3):431-2.
(2006)
Abstract
Riedel RF, Wang X, McCormack M, Toloza E, Montana GS, Schreiber G, Kelley MJ. Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. J Thorac Oncol. 2006 Sep;1(7):692-6.
(2006)
Abstract
Riedel RF, Febbo PG. Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncol. 2005 Aug;1(4):461-6.
(2005)
Abstract
Riedel RF, Crawford J. Small-cell lung cancer: a review of clinical trials. Semin Thorac Cardiovasc Surg. 2003 Oct;15(4):448-56.
(2003)
Abstract
Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, Lee DC. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 1999 Jun;126(12):2739-50.
(1999)
Abstract
Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, Calabretta B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med. 1998 Jun 15;187(12):1995-2007.
(1998)
Abstract
